Bio-Techne stock jumps, with Germany’s Merck KGaA buying the company at a 24% premium.

核心事件：6月25日德国默克集团（Merck KGaA）宣布以113亿美元全现金收购美国生命科学工具供应商Bio-Techne，为其十余年来最大规模交易，交易对价每股73美元，资金来源为现有现金加新增债务。基于当前因子组合评估，默克集团获“持有”评级。 关键数据： 交易较Bio-Techne上一交易日收盘价溢价24%，较其30日均价高36%，对应企业价值倍数（EV/EBITDA）达43.3倍 Bi ...

德国默克（MRK，涨幅 4.93%）宣布，将以 113 亿美元收购美国生命科学仪器供应商 Bio-Techne（TECH，涨幅 19.84%）。这是新任首席执行官上任后，集团扩充实验室仪器业务的关键布局。 本次拟议收购，是默克自十余年前斥资 170 ...

While Bio-Techne stock has underperformed the broader market over the past year, analysts remain moderately bullish about its ...

Valued at a market cap of $9.3 billion, Bio-Techne Corporation (TECH) is a global life sciences company providing tools and bioactive reagents for the research and clinical diagnostic communities.

Q1 beat and Bio-Techne deal drive upside, but valuation looks full. Read here for a detailed investment analysis.

Bio-Techne TECH reported third-quarter fiscal 2025 adjusted earnings per share (EPS) of 56 cents, which surpassed the Zacks Consensus Estimate by 9.8%. The bottom line improved from the year-ago ...

Detailed price information for Bio-Techne Corp (TECH-Q) from The Globe and Mail including charting and trades.

On June 25, 2026, investors tracked deal progress as Bio-Techne shares responded to the proposed buyout terms.

According to a Feb. 17, 2026, SEC filing, Hollow Brook Wealth Management LLC sold out its entire position in Bio-Techne (NASDAQ:TECH) during the fourth quarter of 2025. The fund divested 174,677 ...